Hong Kong stock concept tracking | Two departments: do a good job in prepayment of medical insurance funds. The medical equipment welcomes the comprehensive solution of hospital payment collection (with concept stocks)

The State Medical Insurance Bureau Office and the Ministry of Finance Office issued the "Notice on Doing Well in the Prepayment of Medical Insurance Funds". The "Notice" specifies the standard requirements in terms of policy and system arrangements, application procedures, accounting, and supervision, mainly reflecting the "Three Clarifications" and "Three Regulations". The "Three Clarifications" are as follows: First, clarify the policy connotation. The prepayment is the turnover fund for medical expenses such as drug and medical consumable purchases given by the medical insurance department to designated medical institutions, and should not be used for non-medical expenses such as basic construction investments, daily operations, debt repayment of medical institutions. The original regulations shall be followed in terms of the special prepayment of medical insurance funds for centralized and volume-based procurement of drugs and medical consumables. Second, clarify the conditions for allocation. The safety of funds is the basic premise for implementing prepayment work, and the principle of doing as much as possible and within capacity should be adhered to. In principle, the cumulative balance of the overall region's medical insurance pool and the risk level of medical insurance funds' operation should serve as the conditions and standards for allocating prepayment funds. Third, clarify the expenditure standards. The standard should be determined based on the average monthly expenditure of relevant medical insurance funds in the past one to three years, reasonably determining the basic scale of prepayment funds, and the prepayment scale should be around one month. The National Medical Insurance Administration explained that by regarding "prepayment funds" as "empowerment funds", designated medical institutions can alleviate the pressure of front-end medical expense advance payment, effectively empower the sustainable development of designated medical institutions, thereby providing better medical security for insured populations, promoting the stable operation of pharmaceutical and consumable enterprises, and comprehensively advancing the synergistic development and governance of the "Three Medical" fields to better serve the macroeconomic development and contribute to the social stability. The issue of difficulty in receiving payments by pharmaceutical and medical equipment companies needs to be addressed urgently. With the establishment of the medical insurance prepayment system, the financial turnover pressure of medical institutions will be greatly relieved, and both upstream and downstream accounts are expected to improve. In addition to the establishment of direct settlement systems and online settlement platforms, the payment cycle is expected to be significantly shortened. Zhongtai released a research report stating that the domestic medical device industry is still in a phase of rapid development, and in the short term, the overall industry continues to be under pressure due to high base numbers in diagnosis and treatment and policy disturbances. However, the industry still remains optimistic about the import substitution and globalization driven by innovation, with multiple negative factors having been fully released at the current time point, and the marginal trend is expected to continue to improve. Even though the short-term pressure on internal diagnosis and treatment due to high base numbers and policy disturbances, low-value consumables continue to show a rapid growth trend in the first half of the year. Among them, the revenue growth rate in 24Q3 remains stable, while the profit growth rate continues to be under pressure, with low-value consumables showing continued impressive performance. Pharmaceutical and medical device-related companies include: MICROPORT (00853), MEDBOT-B (02252), MICROPORT NEURO (02172), AK MEDICAL (01789), Beijing Chunlizhengda Medical Instruments (01858), WEIGAO GROUP (01066), GRAND PHARMA (00512), BASECARE-B (02170), AIRDOC-B (02251.HK), etc.